Fresh analysis indicates that patients who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Research printed in a prominent health publication shows that while overweight individuals frequently drop about a fifth of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month once they quit.
"Users using these treatments need to be aware of the danger of rapid rebound weight gain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment weight within about 18 months.
Comparing Treatments
The analysis, which looked at dozens of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills.
Researchers note that individuals who lose weight through lifestyle changes alone generally experience a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Experts propose the mode of action of the jabs accounts for the accelerated regain.
These medications imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal may cause the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement results in hunger is no longer kept in check, making overeating far more likely."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals say that, due to the significant potential of weight regain, the treatment might need to be life-long.
This view is supported by pharmaceutical companies, who say that the findings "highlight the chronic character of excess weight," comparing it to managing conditions like hypertension.
User Experiences
Users who have stopped the jabs report a intense return of appetite.
"I experienced something that goes on and you're instantly extremely hungry," said an individual.
The struggle is worsened if patients have not developed lasting dietary or behavioural modifications during treatment.
Significant Interest
Survey data indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is higher among females than men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, experts caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss relies on combined behavioural management.
